Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Present Value of Free Cash Flow to Equity (FCFE)
- Current Ratio since 2005
- Debt to Equity since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Return on Invested Capital (ROIC)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Invested capital2 | ||||||
Performance Ratio | ||||||
ROIC3 | ||||||
Benchmarks | ||||||
ROIC, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2024 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial data over the five-year period reveal significant fluctuations in several key performance metrics, including net operating profit after taxes (NOPAT), invested capital, and return on invested capital (ROIC).
- Net Operating Profit After Taxes (NOPAT)
- NOPAT shows overall growth with notable annual variation. From 2020 to 2021, NOPAT nearly doubled, increasing from 6,669 million US dollars to 13,349 million US dollars, indicating a strong improvement in operating profitability. The growth continued into 2022, albeit at a slower pace, reaching 14,154 million US dollars. However, there was a sharp decline in 2023, with NOPAT turning negative to -714 million US dollars, signaling operational challenges or extraordinary losses during that year. Recovery occurred in 2024, with NOPAT rebounding sharply to 16,744 million US dollars, the highest value in the period analyzed.
- Invested Capital
- Invested capital demonstrated a generally upward trend with minor fluctuations. Starting at 57,182 million US dollars in 2020, it increased steadily each year until 2022, reaching 73,942 million US dollars. In 2023, there was a slight reduction to 69,966 million US dollars, suggesting possible divestments or asset base contractions. The capital invested rose again in 2024 to 79,426 million US dollars, reaching the peak in the dataset, which could indicate renewed investments or expansion efforts.
- Return on Invested Capital (ROIC)
- ROIC largely mirrored the trends in NOPAT, reflecting shifts in profitability relative to invested capital. The ratio improved significantly from 11.66% in 2020 to 18.87% in 2021 and to 19.14% in 2022, indicating enhanced efficiency in generating returns from capital employed. In 2023, ROIC turned sharply negative to -1.02%, consistent with the negative NOPAT, highlighting poor capital returns during that year. The measure recovered substantially in 2024, reaching 21.08%, the highest efficiency in the period under review, demonstrating improved capital utilization and profitability.
Overall, the data indicate a period marked by growth and improved returns in the initial years, followed by a significant downturn in 2023, with a subsequent strong recovery by 2024. The temporary decline in operating profit and returns suggests an unusual or transitional event impacting financial performance, from which the metrics rebounded effectively by the end of the period.
Decomposition of ROIC
ROIC | = | OPM1 | × | TO2 | × | 1 – CTR3 | |
---|---|---|---|---|---|---|---|
Dec 31, 2024 | = | × | × | ||||
Dec 31, 2023 | = | × | × | ||||
Dec 31, 2022 | = | × | × | ||||
Dec 31, 2021 | = | × | × | ||||
Dec 31, 2020 | = | × | × |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The analysis of the annual financial indicators reveals varied trends over the observed period, reflecting fluctuations in profitability, capital efficiency, and tax impacts.
- Operating Profit Margin (OPM)
- The operating profit margin demonstrates significant variability. Starting at 19.13% in 2020, there is a marked increase to over 30% in 2021 and 2022, followed by a sharp decline to 4.63% in 2023. In 2024, the margin recovers substantially to 32.71%. This pattern suggests a temporary disruption or exceptional expense in 2023 impacting operational efficiency, which is then largely reversed the following year.
- Turnover of Capital (TO)
- Capital turnover shows moderate fluctuations but remains within a relatively narrow range. It decreased from 0.84 in 2020 to 0.69 in 2021, indicating a slight decline in asset utilization efficiency. However, it improves to 0.8 in 2022, peaks at 0.86 in 2023, and declines marginally to 0.81 in 2024. This indicates some operational adjustments or changes in asset base, but overall the company maintains a stable capacity to generate sales from its capital.
- 1 – Effective Cash Tax Rate (CTR)
- The effective cash tax rate fluctuates considerably, starting at 72.65% in 2020 and notably increasing to 89.58% in 2021. It then declines to 79.01% in 2022 but exhibits a significant anomaly in 2023 with a negative value (-25.66%), implying tax credits or refunds received that year. In 2024, the tax rate normalizes back to approximately 79.77%. The irregularity in 2023 may signify an extraordinary tax event affecting cash tax obligations.
- Return on Invested Capital (ROIC)
- The return on invested capital follows a pattern similar to operating profit margin. It shows a rising trend from 11.66% in 2020 to around 19% in 2021 and 2022, then a sharp drop to negative territory (-1.02%) in 2023, before rebounding to 21.08% in 2024. This indicates a temporary impairment or reduced profitability from invested capital in 2023, quickly recovered thereafter.
Overall, the data reveals a year 2023 with significant disruptions impacting profitability, tax rate, and returns, followed by recovery in 2024. Capital turnover remains relatively steady, suggesting that the company’s asset utilization was less affected by the factors influencing other metrics.
Operating Profit Margin (OPM)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Sales | ||||||
Profitability Ratio | ||||||
OPM3 | ||||||
Benchmarks | ||||||
OPM, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
OPM = 100 × NOPBT ÷ Sales
= 100 × ÷ =
4 Click competitor name to see calculations.
- Net Operating Profit Before Taxes (NOPBT)
- The net operating profit before taxes shows a general upward trend over the five-year period, increasing from 9,180 million US dollars in 2020 to 20,990 million in 2024. There was a notable peak in 2022 at 17,914 million, followed by a sharp decline in 2023 to 2,783 million. However, this drop was temporary, as the figure rebounded strongly in 2024.
- Sales
- Sales demonstrate a steady increase throughout the entire period. Starting at 47,994 million US dollars in 2020, sales grew moderately year-over-year to reach 64,168 million by the end of 2024. The growth was relatively consistent, with no years showing a decline, indicating a stable expansion in revenue.
- Operating Profit Margin (OPM)
- The operating profit margin exhibited significant fluctuations over the analyzed years. It increased markedly from 19.13% in 2020 to above 30% in 2021 and 2022, reflecting improved operational efficiency or cost management during this time. In 2023, however, the margin dropped drastically to 4.63%, mirroring the sharp decrease in net operating profit before taxes. By 2024, the margin recovered to 32.71%, indicating a return to higher profitability levels relative to sales.
- Overall Analysis
- The data reveals an overall positive trend in sales and net operating profit over the long term, despite a significant setback in 2023. The temporary decline in both profitability and operating margin that year suggests an unusual event or operational difficulty impacted financial performance. The sharp recovery in 2024 indicates effective corrective actions or favorable business conditions restored profitability. Consistent sales growth supports the company’s revenue stability, while the fluctuating operating margin highlights potential volatility in cost control or expense management during the period researched.
Turnover of Capital (TO)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Sales | ||||||
Invested capital1 | ||||||
Efficiency Ratio | ||||||
TO2 | ||||||
Benchmarks | ||||||
TO, Competitors3 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Invested capital. See details »
2 2024 Calculation
TO = Sales ÷ Invested capital
= ÷ =
3 Click competitor name to see calculations.
The financial data shows several notable trends over the five-year period.
- Sales
- Sales have demonstrated a consistent upward trajectory, increasing from US$47,994 million in 2020 to US$64,168 million in 2024. This represents a steady growth in revenue generation year over year, with the largest absolute increase occurring between 2021 and 2022 and continued growth thereafter, indicating a positive demand and successful market positioning.
- Invested Capital
- Invested capital has experienced fluctuations throughout the period. Starting at US$57,182 million in 2020, it rose significantly to US$70,735 million by 2021, then showed a moderate increase to US$73,942 million in 2022 before decreasing to US$69,966 million in 2023. By 2024, invested capital increased again to US$79,426 million, reaching its highest level in the timeframe. These changes suggest strategic adjustments in capital allocation and investments.
- Turnover of Capital (TO)
- The turnover of capital ratio presents a variable pattern. It declined sharply from 0.84 in 2020 to 0.69 in 2021, likely reflecting the increase in invested capital outpacing sales growth that year. Subsequently, it improved to 0.80 in 2022 and 0.86 in 2023, approaching or exceeding the initial 2020 level. A slight decrease to 0.81 occurred in 2024, but it remained relatively stable. This indicates a generally efficient use of capital to generate sales, with some volatility possibly due to timing of investments or operational performance.
Effective Cash Tax Rate (CTR)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Tax Rate | ||||||
CTR3 | ||||||
Benchmarks | ||||||
CTR, Competitors4 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =
4 Click competitor name to see calculations.
- Cash operating taxes
- The cash operating taxes exhibit variability across the analyzed periods. Starting at 2,510 million US dollars in 2020, there is a notable decrease to 1,553 million in 2021. Following this reduction, the amount increases significantly to 3,760 million in 2022, then slightly decreases to 3,497 million in 2023, before rising again to 4,246 million in 2024. This pattern suggests fluctuations in taxable income or tax-related strategies impacting the tax payments.
- Net operating profit before taxes (NOPBT)
- The net operating profit before taxes shows a general upward trend with some irregularity. The value begins at 9,180 million US dollars in 2020, increasing markedly to 14,902 million in 2021 and then to 17,914 million in 2022. However, in 2023, there is a sharp decline to 2,783 million, representing a significant drop in operating profitability for that period. The figure rebounds strongly in 2024, reaching 20,990 million, the highest level observed in the five-year span. This volatility may reflect operational challenges or extraordinary items in 2023, followed by recovery.
- Effective cash tax rate (CTR)
- The effective cash tax rate shows considerable fluctuation and an unusual spike in 2023. Starting from 27.35% in 2020, the rate falls substantially to 10.42% in 2021, rises to 20.99% in 2022, then dramatically escalates to 125.66% in 2023. This rate exceeds 100%, which may indicate a cash tax payment surpassing pre-tax profits, possibly due to non-recurring items, adjustments, or timing differences in tax payments. In 2024, the rate normalizes to 20.23%, consistent with historical levels.